



Urologic Oncology Team Now Seeing Patients Across the Region

Leading-Edge Technology for Better Outcomes



Adrien Bernstein, MD



Jillian Egan Kelly, MD



Ronald Kaufman Jr., MD



Badar Mian, MD

The Albany Med Health System has a long history of pioneering treatments and surgeries, as well as conducting groundbreaking research in urology. Our urologic oncology team continues this tradition by providing the most advanced, evidence-based care for patients with urologic cancers. We specialize in the diagnosis, treatment, and surgical care for a wide range of urologic cancers, including those of the prostate, bladder, kidney, testis, and penis.

Our team of highly trained urologists is equipped with the expertise to perform the most complex urologic procedures, utilizing industry leading technology, including robotic and minimally invasive surgeries. From initial diagnosis to treatment and recovery, we ensure that each patient receives personalized and compassionate care focused on achieving the best possible outcome.

CONDITIONS TREATED

Prostate cancer *(including clinical trials)*
Bladder tumors, cancers, and masses *(including clinical trials)*
Renal tumors, cancers, and masses
Ureter tumors, cancers, and masses *(including clinical trials)*
Urethral tumors, cancers, and masses
Elevated PSA *(including clinical trials)*
Hematuria *(including clinical trials)*
Renal cyst
Adrenal mass
Penile cancer
Testicular cancer

PROCEDURES

Robotic cystectomy with urinary diversion
Pelvic organ sparing cystectomy (robotic)
Robotic prostatectomy
Prostate biopsy (fusion-guided and transperitoneal)
Robotic partial nephrectomy
Robotic nephrectomy
Robotic nephroureterectomy
Robotic adrenalectomy
Bladder installations for cancer treatments (bcg, intravesical chemotherapy, gene therapy)
Blue light cystoscopy (cysview, for cancer diagnosis)
Penile sparing penile cancer surgery
Transurethral resection of bladder tumors
Urinary diversions (ileal conduit, neobladder, and continent cutaneous pouch)
Ureteroscopic ablation of ureteral tumors
Retroperitoneal lymph node dissection



Ask a Question

Have an urgent need or want more information on a specific service or provider? Contact Physician Liaison, William Brunet, at brunetw@amc.edu or **518-944-9788**.

LOCATIONS

Albany

South Clinical Campus
23 Hackett Blvd.
Albany, NY 12208

Clifton Park

1783 Route 9, Suite 205
Clifton Park, NY 12065

Glens Falls

Glens Falls Hospital
Surgical Specialists
14 Hudson Ave., Floor 2
Glens Falls, NY 12801

Hudson

Medical Office Building
71 Prospect Ave., Suite 190
Hudson, NY 12534

New Patient:

P: **518-262-3341**

F: **518-262-6660**



ALBANY MED Health System

125+
off-site offices

900
full-time physicians

1,520
Hospital Beds

CLINICAL TRIALS

SWOG 1802

Dr. Mian

Cooperative group study comparing standard systemic therapy (SST) alone versus SST with surgery or radiation for advanced prostate cancer.

REQUIREMENTS

- Intact prostate
- Evidence of metastatic disease (bone scan, CT, or MRI), but no brain metastases
- At least 22 but no more than 28 weeks of SST
- No prior local therapy for prostate cancer
- No cancer progression while on SST

Ortho

Dr. Mian | *Quidel Ortho*

Study using VITROS® Immunodiagnostic Products Free PSA III Assay for patients with elevated PSA, normal DRE, and undergoing biopsy within 3 months.

REQUIREMENTS

- Males 50+
- Normal DRE
- PSA Total 3.5-10.5 ng/mL within the last 6 months
- No prior prostate cancer diagnosis
- No 5-alpha reductase inhibitors
- No prostate biopsy within 6 months

ENLIGHTENED

Dr. Kaufman | *Steba Inc.*

Phase 3 study evaluating TOOKAD for low-grade upper tract urothelial cancer.

REQUIREMENTS

- New or recurrent low-grade, non-invasive UTUC
- Up to 2 biopsy-proven tumor lesions, 5-15 mm in diameter, located in the calyces, renal pelvis, or ureter
- Ureter involvement can be in 1 location with < 20mm contiguous length
- No current high-grade or muscle invasive UTUC (within 2 years)
- Biopsy, cytology, and imaging (CT or MRI) within 2 months of screening

BRIDGE EA8212

Dr. Mian

Randomized trial of Intravesical BCG vs. Docetaxel & Gemcitabine for high-grade, non-muscle invasive bladder cancer (BCG-naïve).

REQUIREMENTS

- No history of muscle invasive bladder cancer
- Newly diagnosed within 90 days of randomization
- Not on any immunosuppressive medications
- No prostatic urethral involvement
- HG T1 must have restaging TURBT within 90 days of randomization

LEGEND

Dr. Mian | *En-Gene*

Phase 1/2 study of EG-70 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and high-risk BCG-naïve NMIBC.

REQUIREMENTS

- BCG-unresponsive NMIBC with CIS of the bladder, with or without coexisting papillary Ta/T1 tumors
- BCG-naïve NMIBC with CIS, or BCG-exposed NMIBC with CIS
- Ineligible for or have elected not to undergo cystectomy
- No urothelial cancer outside of the bladder (urethra, ureter, renal pelvis, prostatic ducts)

ADAPT

Dr. Mian | *Investigator Initiated Study*

Study on anti-inflammatory drugs (NSAIDs) and PSA trend.

REQUIREMENTS

- PSA >3 ng/mL
- Normal DRE in the past 2 years
- No history of hypersensitivity to NSAIDs
- No history of bleeding disorders, peptic ulcer disease, or GI bleeding
- Can be on 81mg aspirin

*These clinical trials are specifically offered by the urologic oncology team; however, as an academic medical center, we provide access to a wide range of clinical trials across various specialties.

How to Get Involved:

Enrollment Process:

Contact Urology Research Team
518-262-8579 or amcurologyresearch@amc.edu

All trials are conducted at:

Albany Medical Center Urology
23 Hackett Blvd., Albany, NY 12208
Brenda Romeo, Research Manager